Aurinia Pharmaceuticals (AUPH) Stock: Here’s What You Need To Know

About a week ago Aurinia Pharmaceuticals cratered by 55.75% to close at $1.81 per share. The ironic thing is that the company had announced positive phase 2 results in patients with Lupus Nephritis. If the company posted positive phase 2b results in this patient population then why did the share price tank by so much? … Read more